Effect of Valsartan on the Level of Vwf in Patients with Hypertension and Metabolic Syndrome
GAO Jia-er,JIN Zheng-ming,ZHOU Fen,SUN Jian,ZHU Zhao-hui,HU Shen-jiang
DOI: https://doi.org/10.13191/j.chj.2009.01.79.gaoje.033
2009-01-01
Abstract:AIM To observe the plasma level of von Willebrand factor (vWF) in patients with hypertension and metabolic syndrome (MS) and to measure the changes of vWF after valsartan administration. METHODSThe plasma level of vWF was determined in 22 hypertensive patients with MS before and after valsartan at a dose of 80 mg once daily for 4 weeks and in 29 healthy objects. RESULTSThe plasma level of vWF in patient group was significantly higher than that in the control group [(176±24)% vs (130±26)%, P0.01]. The plasma level of vWF had positive correlation with SBP (r=0.60, P0.01), DBP(r=0.57, P0.01), MAP(r=0.61, P0.01), BMI(r=0.53, P0.01), TG(r=0.36, P0.05), TC(r=0.49, P0.01) and FBG(r=0.45, P0.01). After 4 weeks’ treatment with valsartan, the plasma vWF in patients with hypertension and MS diminished significantly [(160±15)% vs (176±24)%, P0.01]. CONCLUSIONThe plasma level of vWF in patients with MS and hypertension is significantly higher. Valsartan not only controls the blood pressure but also decreases the plasma vWF in a shortterm treatment and improves the endothelial function.